Table 2.

Tumor response with anlotinib in RM-NPC according to RECIST v.1.1

Responses	FAS (n = 39)	PPS (n = 36)
Best overall response, no.; % (95% CI)
CR	0; 0 (0 to 9.0)	0; 0 (0 to 9.7)
PR	8; 20.5 (9.3 to 36.5)	8; 22.2 (10.1 to 39.2)
SD	20; 51.3 (34.8 to 67.6)	20; 55.6 (38.1 to 72.1)
PD	8; 20.5 (9.3 to 36.5)	8; 22.2 (10.1 to 39.2)
NA	3; 7.7 (1.6 to 20.9)	0; 0 (0 to 9.7)
ORR, n (%)	8; 20.5 (9.3 to 36.5)	8; 22.2 (10.1 to 39.2)
DCR, n (%)	28; 71.8 (55.1 to 85.0)	28; 77.8 (60.8 to 89.9)

CR Complete response, DCR Disease control rate, FAS Full analysis set, NA Not assessable, ORR Objective response rate, PD Progressive disease, PPS Per-protocol set, PR Partial response, SD Stable disease